文献速递胸部肿瘤

免疫相关不良事件与阿替利珠单抗疗效在非小细胞肺癌患者中的关联:IMpower130、IMpower132和IMpower150三项3期随机临床试验的汇总分析

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
PubMed 文献 · JAMA Oncol · 2023-01-01

该汇总分析纳入IMpower130、IMpower132和IMpower150三项3期随机试验的2503例晚期非鳞非小细胞肺癌患者,评估免疫相关不良事件(irAE)与阿替利珠单抗疗效的关联。结果显示,在阿替利珠单抗组中,发生1-2级irAE的患者较未发生irAE者总生存期更长,而3-5级irAE与总生存期无显著关联。

要点

  • 在阿替利珠单抗组中,发生1-2级irAE的患者较未发生irAE者总生存期更长。
  • 在阿替利珠单抗组中,发生3-5级irAE与未发生irAE者相比总生存期无显著差异。
  • 上述关联在1、3、6、12个月界标分析中一致。

核心结论

  • 在阿替利珠单抗组和对照组中,发生轻至中度irAE的患者较未发生irAE者总生存期更长,且在各时间界标分析中一致。
  • 这些发现进一步支持含阿替利珠单抗方案用于晚期非鳞非小细胞肺癌的一线治疗。

研究设计与样本

  • IMpower130、IMpower132和IMpower150均为3期、多中心、开放标签、随机临床试验。
  • 汇总分析纳入2503例随机化患者,其中阿替利珠单抗组1577例,对照组926例。
  • 患者为既往未接受化疗的IV期非鳞非小细胞肺癌成人。
  • 本次分析为事后分析,于2022年2月进行。
  • 按治疗分组(含阿替利珠单抗 vs 对照)、irAE状态(有 vs 无)及最高irAE级别(1-2级 vs 3-5级)进行分析。

主要发现

  • 阿替利珠单抗组中,发生irAE者753例,未发生irAE者824例;对照组中,发生irAE者289例,未发生irAE者637例。
  • 阿替利珠单抗组中,1-2级irAE患者(vs 未发生irAE者)在1、3、6、12个月界标分析的总生存期HR(95%CI)分别为0.78(0.65-0.94)、0.74(0.63-0.87)、0.77(0.65-0.90)、0.72(0.59-0.89)。
  • 阿替利珠单抗组中,3-5级irAE患者(vs 未发生irAE者)在1、3、6、12个月界标分析的总生存期HR(95%CI)分别为1.25(0.90-1.72)、1.23(0.93-1.64)、1.1(0.81-1.42)、0.87(0.61-1.25)。

临床怎么用

  • 作者认为,这些发现进一步支持含阿替利珠单抗方案用于晚期非鳞非小细胞肺癌的一线治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immune-related adverse events (irAEs) arising from immune checkpoint inhibitor (ICI) cancer therapy may potentially predict improved outcomes. OBJECTIVE: To evaluate the association between irAEs and atezolizumab efficacy in patients with advanced non-small cell lung cancer (NSCLC) using pooled data from 3 phase 3 ICI studies. DESIGN, SETTING, AND PARTICIPANTS: IMpower130, IMpower132, and IMpower150 were phase 3, multicenter, open-label, randomized clinical trials to evaluate the efficacy and safety of chemoimmunotherapy combinations involving atezolizumab. Participants were chemotherapy-naive adults with stage IV nonsquamous NSCLC. These post hoc analyses were conducted during February 2022. INTERVENTIONS: Eligible patients were randomly assigned 2:1 to receive atezolizumab with carboplatin plus nab-paclitaxel, or chemotherapy alone (IMpower130); 1:1 to receive atezolizumab with carboplatin or cisplatin plus pemetrexed, or chemotherapy alone (IMpower132); and 1:1:1 to receive atezolizumab plus bevacizumab plus carboplatin and paclitaxel, atezolizumab plus carboplatin and paclitaxel, or bevacizumab plus carboplatin and paclitaxel (IMpower150). MAIN OUTCOMES AND MEASURES: Pooled data from IMpower130 (cutoff: March 15, 2018), IMpower132 (cutoff: May 22, 2018), and IMpower150 (cutoff: September 13, 2019) were analyzed by treatment (atezolizumab-containing vs control), irAE status (with vs without), and highest irAE grade (1-2 vs 3-5). To account for immortal bias, a time-dependent Cox model and landmark analyses of irAE occurrence at 1, 3, 6, and 12 months from baseline were used to estimate the hazard ratio (HR) of overall survival (OS). RESULTS: Of 2503 randomized patients, 1577 were in the atezolizumab-containing arm and 926 were in the control arm. The mean (SD) age of patients was 63.1 (9.4) years and 63.0 (9.3) years, and 950 (60.2%) and 569 (61.4%) were male, respectively, in the atezolizumab arm and the control arm. Baseline characteristics were generally balanced between patients with irAEs (atezolizumab, n = 753; control, n = 289) and without (atezolizumab, n = 824; control, n = 637). In the atezolizumab arm, OS HRs (95% CI) in patients with grade 1 to 2 irAEs and grade 3 to 5 irAEs (each vs those without irAEs) in the 1-, 3-, 6-, and 12-month subgroups were 0.78 (0.65-0.94) and 1.25 (0.90-1.72), 0.74 (0.63-0.87) and 1.23 (0.93-1.64), 0.77 (0.65-0.90) and 1.1 (0.81-1.42), and 0.72 (0.59-0.89) and 0.87 (0.61-1.25), respectively. CONCLUSIONS AND RELEVANCE: In this pooled analysis of 3 randomized clinical trials, longer OS was observed in patients with vs without mild to moderate irAEs in both arms and across landmarks. These findings further support the use of first-line atezolizumab-containing regimens for advanced nonsquamous NSCLC. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02367781, NCT02657434, and NCT02366143.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Socinski MA, Jotte RM, Cappuzzo F, et al. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncol. 2023. PMID: 36795388. doi:10.1001/jamaoncol.2022.7711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。